目的 观察西黄丸联合TC方案（紫杉醇联合卡铂）治疗晚期卵巢癌患者的临床疗效。方法 选择南阳市中心医院2021年1月—2024年12月收治的106例晚期卵巢癌患者，采用随机数字表法将患者分为对照组和治疗组，各为53例。对照组给予TC方案，21 d为1个疗程，连续用药3个疗程，治疗组在对照组治疗基础上口服西黄丸治疗，3 g/次，2次/d，连续用药3个月。对比两组临床疗效、生活质量和血清指标。结果 治疗组的客观缓解率（ORR）、疾病控制率（CBR）高于对照组（P＜0.05）。两组治疗后癌症治疗功能评价量表（FACT-G）评分升高（P＜0.05），且治疗组的FACT-G评分高于对照组（P＜0.05）。两组治疗后血清癌胚抗原（CEA）、糖类抗原125（CA125）、人附睾分泌蛋白4（HE4）、B7同源体4（B7-H4）水平下降（P＜0.05），且治疗组血清CEA、CA125、HE4、B7-H4水平低于对照组（P＜0.05）。两组治疗后血清超敏C-反应蛋白（hs-CRP）、白细胞介素（IL）-6、IL-1β、肿瘤坏死因子-α（TNF-α）水平下降（P＜0.05），且治疗组血清hs-CRP、IL-1β、IL-6、TNF-α水平低于对照组（P＜0.05）。两组治疗后CD8⁺下降，CD3⁺、CD4⁺、CD4⁺/CD8⁺、IgG、IgA、IgM升高（P＜0.05），且治疗组CD8⁺低于对照组，CD3⁺、CD4⁺、CD4⁺/CD8⁺、IgG、IgA、IgM高于对照组（P＜0.05）。结论 西黄丸联合TC方案治疗晚期卵巢癌可提高临床疗效，降低肿瘤标志物水平和炎症因子水平，提高免疫功能。

Objective To observe the clinical efficacy of Xihuang Pills combined with TC regimen (paclitaxel combined with carboplatin) in treatment of advanced ovarian cancer. Methods 106 Patients with advanced ovarian cancer admitted to Nanyang Central Hospital from January 2021 to December 2024 were divided into control group and treatment group using a random number table method, with 53 cases in each group. The control group was given the TC regimen, with 21 days as one course and 3 consecutive courses. The treatment group was po administered with Xihuang Pills on the basis of the control group, 3 g/time, twice daily, and continued medication for 3 months. The clinical efficacy, quality of life, and serum indicators were compared between two groups. Results The objective response rate (ORR) and disease control rate (CBR) of the treatment group were higher than those of the control group (P < 0.05). After treatment, the FACT-G score increased in two groups (P < 0.05), and the FACT-G score of the treatment group was higher than that of the control group (P < 0.05). After treatment, the serum levels of CEA, CA125, HE4, and B7-H4 decreased in two groups (P < 0.05), and the serum levels of CEA, CA125, HE4, and B7-H4 in the treatment group were lower than those in the control group (P < 0.05). After treatment, the serum levels of hs-CRP, IL-6, IL-1β, and TNF-α decreased in two groups (P < 0.05), and the serum levels of hs-CRP, IL-1β, IL-6, and TNF-α in the treatment group were lower than those in the control group (P < 0.05). After treatment, CD8⁺ decreased in two groups, while CD3⁺, CD4⁺, CD4⁺/CD8⁺, IgG, IgA, and IgM increased (P < 0.05). CD8⁺ level of in the treatment group was lower than that in the control group, while CD3⁺, CD4⁺, CD4⁺/CD8⁺, IgG, IgA, and IgM were higher than those in the control group (P < 0.05). Conclusion The combination of Xihuang Pills and TC regimen in treatment of advanced ovarian cancer can improve clinical efficacy, reduce tumor marker levels and inflammatory factor levels, and enhance immune function.

R979.1

河南省医学科技攻关计划联合共建项目（LHGJ20230975）